奥克替林 | 47166-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 中文名称: 奥克替林
• 中文别名: 欧曲塔林
• 英文名称: Octriptyline Phosphate
• 英文别名: Octriptyline；N-methyl-3-(11-tetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaenylidene)propan-1-amine
• CAS: 47166-67-6
• 化学式: C₂₀H₂₁N
• 分子量: 275.393
• InChiKey: MILRTYCRJIRPKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-二苯并环庚烯酮 在 sodium methylate 作用下， 生成 奥克替林
  参考文献：
  名称：

  氨基烷基二苯并（a，e）环丙烷（c）环庚烯衍生物。一系列有效的抗抑郁药。

  摘要：

  DOI：

  10.1021/jm00247a015

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use
  申请人：Christian T. Samuel

  公开号：US20060189547A1

  公开（公告）日：2006-08-24

  Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide.

  亲水性N-连接药物组合物，其制备方法和在神经轴向药物输送中的使用，包括一种糖基中枢神经系统作用前药化合物，通过酰胺或胺键与糖苷共价连接，并且配方包括添加剂、稳定剂、载体、粘合剂、缓冲剂、赋形剂、润肤剂、破碎剂、润滑剂、抗微生物剂或防腐剂，但前提是糖苷基团不是环糊精或葡萄糖醛酸盐。
• Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use
  申请人：Christian Samuel T.

  公开号：US20110237544A1

  公开（公告）日：2011-09-29

  Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide.

  亲水性N-连接的药物组成物、其制备方法和在神经轴药物输送中的使用，包括一种糖基CNS作用的前药化合物，通过酰胺或胺键与糖分子共价连接，并由添加剂、稳定剂、载体、粘合剂、缓冲剂、赋形剂、润肤剂、崩解剂、润滑剂、抗微生物剂或防腐剂组成的制剂，前提是糖分子部分不是环糊精或葡糖醛酸盐。
• Pharmaceutical formulations for parenteral use
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0335545A2

  公开（公告）日：1989-10-04

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly'soluble in water and/or which are unstable in water, combined with a hydroxypropyl,hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivative of 3-or γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  不溶于水或只能少量溶于水和/或在水中不稳定的药物的肠外水溶液与 3-或 γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物结合使用，可以缓解肠外给药后药物在注射部位和/或肺部或其他器官沉淀的问题。